Client List
Request Client Information
Client Press Releases
Client Events
Testimonials
5/16/2013
MAXIMUS Launches Independent Medical and Bill Review Services for California Workers’ Compensation Programs
5/16/2013
Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results
5/15/2013
SIGMA-TAU RECEIVES INNOVATION AWARD FROM THE NATIONAL ORGANIZATION FOR RARE DISORDERS FOR ITS ADVANCEMENTS IN RARE DISEASES
5/15/2013
MAXIMUS to Operate the Vermont Health Connect Customer Support Center
5/13/2013
PDI Reports 2013 First Quarter Financial Results
5/9/2013
MAXIMUS Reports Financial Results for Second Quarter of Fiscal 2013 Company Reiterates Guidance
5/8/2013
Retrophin Names Marc L. Panoff as Chief Financial Officer
5/3/2013
CIPHER REPORTS RECORD FINANCIAL RESULTS FOR Q1 2013
5/1/2013
SIGMA-TAU PHARMACEUTICALS LAUNCHES CYSTARAN™ FOR THE TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
5/1/2013
PDI, Inc. to Hold First Quarter 2013 Financial Results Conference Call on Tuesday, May 14, 2013
4/29/2013
DAVE LEMUS PROMOTED TO CHIEF EXECUTIVE OFFICER OF SIGMA-TAU PHARMACEUTICALS, INC.
4/25/2013
Highlights for the first quarter 2013
4/25/2013
Alexion Broadens and Strengthens its Executive Leadership Team
4/25/2013
Retrophin Names Horacio Plotkin, M.D. as Chief Medical Officer
4/25/2013
Alexion Reports First Quarter 2013 Results
4/24/2013
MAXIMUS Schedules Fiscal 2013 Second Quarter Conference Call
4/18/2013
MAXIMUS Announces Two-for-One Stock Split and Quarterly Cash Dividend
4/17/2013
NEW DATA SHOW PHARMATHENE’S RECOMBINANT BIOSCAVENGER BINDS TO A BROAD SPECTRUM OF CHEMICAL NERVE AGENTS
4/11/2013
Alexion Pharmaceuticals to Report First Quarter 2013 Results on Thursday, April 25, 2013
4/10/2013
PHOTOCURE ANNOUNCES POSITIVE FINAL RESULTS OF PHASE 2B CEVIRA® STUDY
4/8/2013
Retrophin Sponsors Seventh International NBIA Disorders Association Family Conference
4/3/2013
Updated European Association of Urology Guidelines Strengthen Recommendation on Use of Hexvix®
4/3/2013
TetraLogic Pharmaceuticals Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2013
4/2/2013
Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results
4/2/2013
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-end 2012 Financial Results
3/27/2013
Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse™
3/13/2013
PDI, Inc. Announces $17 Million Multi-Year Sales Contract
3/7/2013
ADMA Biologics Commences Pivotal Phase III Clinical Study of RI-002 in PIDD Patients
3/7/2013
Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
3/6/2013
ADMA Biologics Reports 2012 Year End Financial and Operational Results
3/6/2013
PDI Reports 2012 Fourth Quarter and Year End Financial Results
3/5/2013
Catalyst Pharmaceutical Partners Appoints Dr. Bernardino Mosquera as Vice President of Clinical Operations
3/1/2013
CIPHER REPORTS RECORD FINANCIAL RESULTS FOR 2012
2/28/2013
Alexion Joins Eurordis, NORD and Patient Organizations Worldwide in Celebrating Rare Disease Day 2013
2/28/2013
PDI, Inc. to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on Thursday, March 7, 2013
2/21/2013
Catalyst Pharmaceutical Partners Launches New Website
2/14/2013
Alexion Reports Fourth Quarter and Full Year 2012 Results
2/12/2013
Retrophin Raises $10.0 Million in Private Placement
2/11/2013
Catalyst Pharmaceutical Partners Provides Update on Research and Development Pipeline
2/7/2013
Alexion Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
1/28/2013
TetraLogic Pharmaceuticals Announces Decision to Grant Japanese Patent on Birinapant
12/10/2012
TetraLogic Pharmaceuticals Announces Presentation on Smac Mimetic Birinapant at American Society of Hematology (ASH) Annual Meeting
12/10/2012
New Data Highlighting Long-Term Efficacy and Safety Outcomes of PNH Patients Treated with Soliris® Reported at ASH Annual Meeting
12/6/2012
PHOTOCURE ANNOUNCES POSITIVE RESULTS OF CEVIRA® STUDY RESULTS DEMONSTRATE SIGNIFICANT EFFICACY IN TREATMENT OF LESIONS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN PATIENTS WITH PRECANCEROUS LESIONS OF THE CERVIX
12/6/2012
Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two Additional Indications: Triple Negative and Inflammatory Breast Cancers
12/6/2012
TetraLogic Pharmaceuticals’ Smac Mimetic Birinapant Selected for Oral Presentation at the 17th Japanese Foundation for Cancer Research – International Symposium on Cancer Chemotherapy
11/16/2012
Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results
11/14/2012
Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
11/8/2012
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II(b) Trial for Cocaine Addiction
11/7/2012
Researchers to Present Additional Data on Soliris® (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting
11/5/2012
Omthera Pharmaceuticals Presents Successful Phase 3 Results from EVOLVE and ESPRIT Clinical Studies for Epanova™; Both Trials Meet Primary and Secondary Endpoints
11/3/2012
Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients with aHUS
11/3/2012
New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS
10/22/2012
PDI, Inc. Promotes Gerald R. Melillo, Jr. to President, Sales Services
10/10/2012
Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS and STEC-HUS at ASN Annual Meeting
10/9/2012
TetraLogic Pharmaceuticals Granted Third U.S. Patent on Birinapant
10/9/2012
Data from Investigator-Initiated Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe Relapsing Neuromyelitis Optica (NMO) Presented at the American Neurological Association (ANA) Annual Meeting
10/4/2012
Bio-Path Holdings Adds New Board Member
8/16/2012
Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results
7/25/2012
Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias
7/24/2012
PDI, Inc. Announces $29 Million in New and Extended Sales Contracts
7/24/2012
ADMA Biologics Appoints Plasma Industry Leader Lawrence Guiheen to Board of Directors
7/23/2012
ADMA Biologics Appoints James Mond, M.D., Ph.D. as Chief Medical and Scientific Officer
7/18/2012
PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
6/17/2012
New Data Show Majority of Patients with aHUS Experienced Systemic Multi-Organ Complications Prior to Treatment
6/4/2012
Data from Phase 1 and Phase 1B Studies of NewLink Genetics’ IDO Pathway Inhibitor (NLG8189) Presented at 2012 ASCO Annual Meeting
6/4/2012
NewLink Genetics reports Two- and Three-year Overall Survival data from its Phase-2 HyperAcute® Pancreas (algenpantucel-L) Immunotherapy trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
6/4/2012
Bio-Path Holdings Shares Commence Trading On OTCQX, The Top Tier Of The OTC Market
6/4/2012
NewLink Genetics HyperAcute® Lung (tergenpumatucel-L) Immunotherapy Demonstrates a Correlation Between Immune Response and Survival in Patients with Non-Small Cell Lung Cancer
6/1/2012
Data from an Investigator-Initiated Phase 2 Study of NewLink Genetics' HyperAcute® Melanoma Immunotherapy Published in 2012 ASCO Annual Meeting Abstracts
5/29/2012
Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
5/24/2012
PDI, Inc. Announces New Business Win Valued At $57 Million
5/17/2012
Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results
5/14/2012
PDI, Inc. Announces $16 Million in New, Renewal Sales Contracts
5/11/2012
New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris®) in Patients with STEC-HUS
4/26/2012
Complix’ Alphabody™ Protein Therapeutics Demonstrate Activity against both Undruggable Extracellular and Intracellular Disease Targets
4/3/2012
Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results
3/29/2012
Asfotase Alfa Significantly Decreased TNSALP Substrates and Improved 6-Minute Walk Test Results in Adolescents and Adults with Hypophosphatasia (HPP)
3/7/2012
New England Journal of Medicine Publishes Data from Phase 2 Study of Asfotase Alfa in Life-Threatening Hypophosphatasia
2/7/2012
Alexion Completes Acquisition of Enobia Pharma Corp.
2/7/2012
Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
2/2/2012
ThromboGenics Announces that the FDA Intends to Grant Ocriplasmin Priority Review
12/28/2011
Alexion to Acquire Enobia Pharma Corp. and First Potential Treatment for Patients with Hypophosphatasia (HPP)
12/23/2011
ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA
12/16/2011
ThromboGenics and BioInvent Complete Enrollment of Phase IIb Trial with TB-402 ahead of schedule
12/13/2011
Bio-Path Holdings’ Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose
11/29/2011
Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
11/29/2011
Soliris® (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
11/24/2011
ThromboGenics Appoints Thomas Clay as New Board Member
11/15/2011
Bio-Path Holdings Reports Third Quarter 2011 Financial Results
10/20/2011
ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day
10/19/2011
ThromboGenics Announces EMA Acceptance for Review of Marketing Authorisation Application for Ocriplasmin
10/4/2011
Initial Data from Bio-Path Holding’s Phase I Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting
9/23/2011
Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
9/23/2011
Alexion Receives CHMP Positive Opinion for Soliris® (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European Union
9/14/2011
Phase 2 Study of Eculizumab (Soliris®) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual Meeting
8/22/2011
ThromboGenics Announces New Phase III Ocriplasmin Data Presented at the 2011 Annual Meeting of the American Society of Retina Specialists (ASRS)
8/15/2011
Bio-Path Holdings Reports Second Quarter 2011 Financial Results
8/11/2011
First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
8/9/2011
ThromboGenics on Track to File Ocriplasmin by End of 2011
7/19/2011
Bio-Path Holdings Announces the Relocation of Corporate Headquarters to Houston, Texas
6/20/2011
Alexion Initiates Clinical Trial of Eculizumab as a Potential Treatment for Patients with STEC-HUS in Expanded Response to EHEC Crisis in Germany
6/14/2011
METHYLGENE REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
6/11/2011
New Data Show Renal Impairment Is Strong Predictor of Early Death in Patients with PNH
6/11/2011
Researchers Present Final Data from Phase 2 Studies of Soliris® (eculizumab) in Patients with aHUS
6/3/2011
METHYLGENE REPORTS CLINICAL DATA FOR MGCD265 AT THE 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
6/1/2011
FDA Grants Priority Review for Alexion’s sBLA for Soliris®(eculizumab) as a Treatment for Patients with atypical Hemolytic Uremic Syndrome (aHUS)
5/23/2011
Researchers to Present Nine Studies on Soliris® (eculizumab) in Patients with PNH and aHUS at EHA Congress
5/19/2011
METHYLGENE TO PRESENT MGCD265 DATA AT THE 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/17/2011
Bio-Path Holdings Reports First Quarter 2011 Financial Results
5/16/2011
ThromboGenics and BioInvent Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche
5/12/2011
Alexion Shareholders Approve Increase in Authorized Shares For Previously Announced Stock Split
4/28/2011
Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research
4/27/2011
ThromboGenics and BioInvent Have Dosed the First Patient in Phase IIb Trial of TB-402 (Anti-Factor VIII) for Venous Thromboembolism (VTE) Prophylaxis
4/7/2011
Alexion Submits Applications for Soliris® (eculizumab) as a Treatment for Patients with atypical Hemolytic Uremic Syndrome (aHUS) in the United States and European Union
4/5/2011
METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD265 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
4/1/2011
Thrombogenics increases share capital through warrant exercises
3/31/2011
Bio-Path Holdings Reports Fiscal Year 2010 Operational and Financial Results
3/30/2011
Alexion Announces Two-For-One Stock Split
3/30/2011
METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2010 FINANCIAL RESULTS
3/14/2011
Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
3/11/2011
ThromboGenics NV – Business Update
3/10/2011
ThromboGenics Announces Business Update and 2010 Full-Year Results
2/28/2011
Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
2/28/2011
Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
2/28/2011
Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2011
2/11/2011
Positive TB-402 (Anti-Factor VIII Antibody) Phase II Data Published in Journal of Thrombosis and Haemostasis
2/10/2011
Alexion Reports Fourth Quarter and Full Year 2010 Results
2/10/2011
Alexion Acquires Investigational Therapy for Infants Suffering From Catastrophic, Ultra-Rare Genetic Neurologic Disorder
1/31/2011
Alexion Acquires Taligen Therapeutics and Creates Translational Medicine Group to Accelerate Development of Expanded Portfolio
1/21/2011
CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Targeted to Protein-Protein Binding Sites Inhibit Pancreatic Cancer Cells Growth
1/18/2011
CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
1/7/2011
Omthera Pharmaceuticals Reports Favorable Pharmacokinetics Data from ECLIPSE Trial
12/6/2010
Long-Term Efficacy, Safety and Survival Outcomes of PNH Patients Treated with Soliris® (eculizumab) Reported at ASH Annual Meeting
12/6/2010
Hemolysis Is Associated with Increased Mortality and Thrombosis in Patients with PNH
12/5/2010
Alexion Reports Results from First Clinical Trial of Novel Anti-Cancer Antibody Samalizumab at ASH Annual Meeting
11/29/2010
METHYLGENE TO PRESENT CLINICAL DATA AT THE 52nd AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
11/24/2010
Glycotex, Inc. Awarded Cash Grant Under the U.S. Government Qualifying Therapeutic Discovery Program
11/20/2010
Phase 2 Study of Eculizumab (Soliris®) in Patients with aHUS Resistant to Plasma Therapy Met Primary and Secondary Endpoints with High Statistical and Clinical Significance
11/18/2010
METHYLGENE PRESENTS ENCOURAGING CLINICAL DATA FOR MGCD265 IN SOLID TUMOR CANCERS AT THE 22nd EORTC-NCI-AACR ANNUAL MEETING
11/15/2010
Bio-Path Holdings Reports Third Quarter 2010 Financial Results
11/12/2010
METHYLGENE REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE FOR MGCD265
11/10/2010
METHYLGENE TO PRESENT AT THE 22ND EORTC-NCI-AACR SYMPOSIUM
11/8/2010
Researchers to Present New Long-Term Data on Soliris® (eculizumab) in Patients with PNH at the ASH Annual Meeting
11/5/2010
ThromboGenics NV – Business Update
11/3/2010
Bio-Path Holdings Awarded Grant From The U.S. Government’s Qualifying Therapeutic Discovery Project Program
11/2/2010
Nile Therapeutics Phase 2 Study of CD-NP in Patients with Acute Decompensated Heart Failure meets Primary Endpoint, Has Favorable Trends on Renal Function
10/20/2010
METHYLGENE’S LEAD PROGRAM, MGCD265, NOMINATED “TOP TEN ONCOLOGY PROJECTS TO WATCH” BY WINDHOVER AND CAMPBELL ALLIANCE
9/30/2010
ThromboGenics Signs Deal with MSD for Long-Term Commercial Supply of Microplasmin
9/28/2010
METHYLGENE ISSUED KEY PATENTS FOR LEAD ONCOLOGY PROGRAM
9/16/2010
METHYLGENE ENTERS INTO $15 MILLION EQUITY LINE FACILITY AGREEMENT
9/13/2010
METHYLGENE ANNOUNCES CHANGES TO SENIOR MANAGEMENT
9/13/2010
METHYLGENE PRESENTS PHASE I DATA FOR ITS NOVEL ANTIFUNGAL AGENT, MGCD290, AT THE 50TH ANNUAL ICAAC MEETING
9/6/2010
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin’s Potential to Transform the Treatment of Retinal Disorders
9/1/2010
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
8/26/2010
ThromboGenics NV Announces 2010 First Half Results
8/23/2010
ALEXION RECEIVES FDA APPROVAL OF RHODE ISLAND MANUFACTURING FACILITY FOR SOLIRIS® SUPPLY
7/30/2010
METHYLGENE REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE FOR MGCD265
7/22/2010
ALEXION REPORTS SECOND QUARTER 2010 RESULTS
7/15/2010
ThromboGenics Announces Publication of Positive Microplasmin Phase II Data in the Journal Retina
7/9/2010
Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII) Presented at the 21st International Congress on Thrombosis in Milan, Italy
7/1/2010
ThromboGenics to Present Results of Second Phase III Trial of Microplasmin at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress
6/30/2010
METHYLGENE FURTHER EXTENDS COLLABORATION WITH OTSUKA PHARMACEUTICAL FOR THE DEVELOPMENT OF KINASE INHIBITORS FOR TREATMENT OF OCULAR DISEASES
6/15/2010
Early Clinical Experience and Basic Science Support Further Investigation of Soliris® (eculizumab) for the Treatment of Patients with Thrombotic Microangiopathy
6/14/2010
Substantial Disease Burden of PNH Demonstrated in Data from International and Asian Patient Registries Presented at European Hematology Association
6/7/2010
METHYLGENE PRESENTS CLINICAL DATA FOR MOCETINOSTAT AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2010 ANNUAL MEETING
6/7/2010
METHYLGENE PRESENTS ENCOURAGING CLINICAL AND PRECLINICAL DATA FOR MGCD265 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2010 ANNUAL MEETING
6/7/2010
ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
6/1/2010
Alexion Announces the Appointment of Ann M. Veneman to Its Board of Directors
5/21/2010
DATA FROM METHYLGENE’S MGCD265 AND MOCETINOSTAT CLINICAL TRIALS TO BE PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/19/2010
METHYLGENE ANNOUNCES COMPLETION OF NON-DILUTIVE FINANCING
5/17/2010
ThromboGenics and BioInvent to Receive €10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
5/14/2010
METHYLGENE SHAREHOLDERS APPROVE NON-DILUTIVE FINANCING OF UP TO $9.1 MILLION AND COMPANY REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS
5/11/2010
ThromboGenics NV – Business Update
5/6/2010
ThromboGenics and BioInvent Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)
4/30/2010
Research to be Presented at the American Transplant Congress Examines the Role of Terminal Complement Inhibition in the Treatment of Kidney Transplantation Patients
4/23/2010
METHYLGENE ANNOUNCES ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND PROVIDES CORPORATE UPDATE
4/20/2010
METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD265 (A MULTI-TARGETED MET KINASE INHIBITOR) AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
4/20/2010
ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion (VMA)
4/16/2010
METHYLGENE TO PRESENT MGCD265 DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
4/16/2010
Alexion’s Soliris® (Eculizumab) Receives Marketing Approval in Japan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
2/24/2010
EMISPHERE TECHNOLOGIES ANNOUNCES EXTENSION OF MATURITY DATE FOR CONVERTIBLE PROMISSORY NOTE
2/9/2010
ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2/8/2010
NEXMED RECEIVES OVER $2.7 MILLION CASH INFUSION
2/1/2010
NEXMED GRANTED REQUEST FOR CONTINUED LISTING ON NASDAQ
12/16/2009
ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
12/11/2009
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-related Macular Degeneration (AMD)
12/7/2009
Soliris® Reduced Hemolysis, Lowered Thrombosis Rate and Improved Quality of Life in Patients with PNHWho Had Previously Never Been Transfused
12/7/2009
Soliris® Reversed Thrombocytopenia in Patients with Both PNH and Pre-Existing Thrombocytopenia in Study Presented at ASH Annual Meeting
12/6/2009
Soliris® Reduced Hemolysis, Decreased Transfusion Requirements and Improved Fatigue in Patients with PNH and Bone Marrow Insufficiency Disorders
12/6/2009
Researchers Report Clinical Association Between Type II PNH Cells and Thrombocytopenia
12/4/2009
Long-Term Soliris® Treatment Resulted in Sustained Reduction in Hemolysis and Improved Kidney Function in Japanese Patients with PNH
11/17/2009
METHYLGENE REPORTS FAVORABLE PHASE I DATA FOR MGCD265 IN SOLID TUMORS AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE
11/17/2009
ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid Tumours
11/5/2009
METHYLGENE REPORTS THIRD QUARTER 2009 FINANCIAL RESULTS
11/4/2009
ThromboGenics NV Business Update
10/20/2009
STUDY RESULTS: NOVEL ORAL PTH FORMULATION USING EMISPHERE’S ELIGEN® TECHNOLOGY SHOWED POTENTIAL THERAPEUTICAL ADVANTAGES TO AVAILABLE INJECTABLE PTH IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN
10/15/2009
STUDY RESULTS SUGGEST ORAL SALMON CALCITONIN USING ELIGEN® DRUG DELIVERY TECHNOLOGY MAY REDUCE CARTILAGE AND BONE DEGRADATION IN OSTEOARTHRITIS
10/14/2009
METHYLGENE ANNOUNCES EQUITY INVESTMENT FROM OTSUKA PHARMACEUTICAL CO., LTD.
10/13/2009
Transdel Pharmaceuticals Appoints Dr. Joachim P.H. Schupp as Chief Medical Officer
10/8/2009
EMISPHERE TECHNOLOGIES INTRODUCES FIRST COMMERCIALLY AVAILABLE PRODUCT, ORAL ELIGEN® B12
10/6/2009
Transdel Pharmaceuticals Announces Positive Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel®
9/22/2009
Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
9/21/2009
METHYLGENE TO RESUME DEVELOPMENT OF ITS HDAC INHIBITOR, MGCD0103 (MOCETINOSTAT)
9/21/2009
Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
9/15/2009
METHYLGENE PRESENTS PHASE I DATA FOR ITS NOVEL ANTIFUNGAL AGENT, MGCD290, AT THE 49TH ANNUAL ICAAC MEETING
9/14/2009
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS BETA-LACTAMASE INHIBITOR, MG96077, AT THE 49TH ANNUAL ICAAC MEETING
9/9/2009
METHYLGENE AND OTSUKA PHARMACEUTICAL CO. LTD. EXTEND FUNDED RESEARCH COLLABORATION
9/8/2009
Emisphere Technologies Announces Publication in Clinical Pharmacology and Therapeutics of Encouraging Data from an Independent Clinical Study of an Oral Eligen-GLP-1 Formulation on Glucose Homeostasis
9/8/2009
METHYLGENE TO PRESENT DATA AT THE 49TH ANNUAL ICAAC MEETING
9/2/2009
METHYLGENE INITIATES PHASE II PROGRAM FOR MGCD265 IN SOLID TUMORS AND NON-SMALL CELL LUNG CANCER PATIENTS
8/21/2009
EMISPHERE TECHNOLOGIES ANNOUNCES CLOSING OF $4 MILLION REGISTERED DIRECT OFFERING AND $4 MILLION PRIVATE PLACEMENT
8/21/2009
MediciNova and Avigen Enter Into Definitive Agreement for Business Combination
8/19/2009
Emisphere Technologies to Raise $4 Million in Registered Direct Offering and Additional $4 Million in Private Placement
8/14/2009
MediciNova Reports Second Quarter 2009 Results
8/11/2009
Emisphere Technologies Announces Financial and Operational Results for the Second Quarter and First Six Months of 2009
8/10/2009
EMISPHERE TECHNOLOGIES INTRODUCES FIRST COMMERCIALLY AVAILABLE PRODUCT, ORAL ELIGEN® B12
8/6/2009
EUROPEAN COMMISSION AND U.S. FDA GRANT ALEXION’S SOLIRIS® (ECULIZUMAB) ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
7/31/2009
METHYLGENE REPORTS SECOND QUARTER 2009 FINANCIAL RESULTS
7/28/2009
EMISPHERE’S SNAC CARRIER ACHIEVES GRAS STATUS FOR USE WITH NUTRIENTS ADDED TO FOODS AND DIETARY SUPPLEMENTS
7/23/2009
ALEXION REPORTS SECOND QUARTER 2009 RESULTS
7/21/2009
MediciNova to Evaluate MN-221 for the Treatment of Chronic Obstructive Pulmonary Disease Exacerbations
7/13/2009
MediciNova Announces Proposed Final Protocol for its Phase II Placebo-controlled Clinical Trial Evaluating MN-221 in Patients with Severe, Acute Exacerbations of Asthma
6/25/2009
MediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination
6/22/2009
Arlene Morris Joins MediciNova's Audit Committee
6/22/2009
EMISPHERE TECHNOLOGIES, INC. AND SYRACUSE UNIVERSITY ENTER RESEARCH AGREEMENT TO TEST ORAL DRUG DELIVERY SYSTEMS
6/19/2009
Alexion Extends Its Commitment to a Green Footprint Through Its Ambitious New Solar Energy System
6/10/2009
Alexion's Soliris® Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
6/8/2009
EMISPHERE TECHNOLOGIES, INC. RECEIVES NASDAQ PANEL DECISION
6/1/2009
EMISPHERE TECHNOLOGIES ANNOUNCES THE COMPLETION OF ENROLLMENT IN SECOND PHASE III STUDY FOR ORAL OSTEOARTHRITIS TREATMENT UTILIZING PROPRIETARY ELIGEN® TECHNOLOGY
5/29/2009
New Study Results Verify That PNH Cells Are Found in Majority of Patients with Bone Marrow Failure Syndromes
5/28/2009
METHYLGENE REPORTS FAVORABLE PRELIMINARY PHASE I DATA FOR MGCD265, ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, AT ASCO ANNUAL MEETING
5/28/2009
MediciNova Announces Plan to Modify its Phase II Placebo-controlled Clinical Trial Evaluating MN-221 in Patients with Severe, Acute Exacerbations of Asthma
5/28/2009
RESEARCHERS TO REPORT ON THE INVESTIGATIONAL USE OF ALEXION’S SOLIRIS® (ECULIZUMAB) TO PREVENT ANTIBODY-MEDIATED REJECTION IN HIGH-RISK KIDNEY TRANSPLANT PATIENTS
5/26/2009
EMISPHERE TECHNOLOGIES REPORTS ENCOURAGING DATA FROM INDEPENDENT CLINICAL STUDY ASSESSING THE EFFECTS OF ORAL GLP-1 AND PYY3-36, COMBINED WITH ELIGEN® TECHNOLOGY ON APPETITE SUPRESSION
5/21/2009
EMISPHERE TECHNOLOGIES RECEIVES MILESTONE PAYMENT FROM MANNKIND CORPORATION
5/19/2009
EMISPHERE TECHNOLOGIES APPOINTS FRANKLIN M. BERGER TO ITS BOARD OF DIRECTORS
5/15/2009
MediciNova Reports First Quarter 2009 Results
5/8/2009
METHYLGENE REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS
5/7/2009
EMISPHERE TECHNOLOGIES, INC. REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS
4/24/2009
Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
4/23/2009
ALEXION REPORTS FIRST QUARTER 2009 RESULTS
4/22/2009
MediciNova Reports Final Data from Phase II MN-221 Emergency Department Clinical Trial (MN-221-CL-006); Hospitalization Rates Decrease 45 Percent with MN-221 Plus Standardized Care in Asthma Patients
4/22/2009
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
4/22/2009
Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
4/21/2009
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS SECOND ORAL KINASE INHIBITOR, MG516, AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
4/8/2009
Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
4/7/2009
Glycotex’ Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
4/2/2009
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
4/1/2009
Alexion Submits NDA in Japan for Soliris(R) (eculizumab) as a Treatment for Patients with PNH
3/31/2009
TorreyPines Therapeutics Reduces Workforce to Three Employees
3/31/2009
MediciNova Reports Fourth Quarter and Full Year 2008 Results
3/30/2009
Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
3/30/2009
METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2008 FINANCIAL RESULTS
3/27/2009
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
3/23/2009
Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
3/19/2009
Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
3/12/2009
MediciNova Sends Letter to Avigen Board of Directors
2/27/2009
ALEXION JOINS NORD AND EURORDIS IN SUPPORTING THE GOALS OF RARE DISEASE DAY
2/25/2009
Alexion’s Soliris(R) (eculizumab) Receives Marketing Approval in Australia for All Patients with PNH
2/23/2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
2/11/2009
First Multiple Dose Clinical Trial of TorreyPines Therapeutics’ Oral Compound NGX426 Demonstrates Compound is Safe and Well-Tolerated
2/9/2009
MediciNova Reaffirms Proposal to Acquire Avigen, Inc.
1/29/2009
ALEXION’S SOLIRIS(R) (ECULIZUMAB) RECEIVES MARKETING APPROVAL IN CANADA FOR ALL PATIENTS WITH PNH
1/29/2009
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES CASE REPORTS ON THE INVESTIGATIONAL USE OF SOLIRIS (ECULIZUMAB) IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
1/22/2009
PII AND NEXMED ENTER INTO STRATEGIC COLLABORATION AGREEMENT FOR NEXMED’S NEXACT® DRUG DELIVERY PLATFORM
1/13/2009
Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
1/13/2009
The Immune Tolerance Institute, Sequenom and the University of California, San Francisco to Develop Advanced Diagnostic Test for Severe Combined Immunodeficiency in Newborns
1/12/2009
MediciNova Reports Interim Phase II Data from MN-221 Emergency Department Study
1/12/2009
SOLIRIS(R) RECEIVES ORPHAN DRUG DESIGNATION IN JAPAN
1/5/2009
Micromet Key Events for 2009
1/5/2009
ALEXION PHARMACEUTICALS AND PDL BIOPHARMA RESOLVE PATENT DISPUTE
12/23/2008
MediciNova Proposes to Acquire Avigen, Inc.
12/18/2008
RHEI PHARMACEUTICALS RECEIVES APPROVAL IN CHINA FOR ITS DRS. HANS SCHREUDER SCAR TREATMENT PRODUCT
12/18/2008
Living Cell Technologies Announces Collaboration with Centocor Research & Development, Inc.
12/11/2008
Preclinical Studies Suggest that Living Cell Technologies’ NeurotrophinCell is Effective in Parkinson’s disease
12/9/2008
Micromet Presents Updated Data on the Phase 1 Trial Studying Blinatumomab (MT103/MEDI-538) in Patients with Advanced Non - Hodgkin's Lymphoma
12/9/2008
SOLIRIS® REDUCED MEASURES OF THROMBOSIS AND INFLAMMATION, AND DECREASED INDICATORS OF PULMONARY HYPERTENSION, IN PATIENTS WITH PNH
12/8/2008
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
12/8/2008
ALEXION REPORTS POSITIVE RESULTS FROM AEGIS REGISTRATION STUDY OF SOLIRIS IN JAPANESE PATIENTS WITH PNH
12/7/2008
FIRST CLINICAL EXPERIENCE WITH SOLIRIS® IN TREATING PATIENTS WITH TWO RARE COMPLEMENT-MEDIATED DISEASES PRESENTED AT ASH ANNUAL MEETING
12/5/2008
RHEI PHARMACEUTICALS ANNOUNCES THE INITIATION OF THE FINAL CLINICAL STUDY FOR APPROVAL OF TIBOZOLE IN CHINA
12/2/2008
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
12/1/2008
TorreyPines’ NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
11/25/2008
TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
11/20/2008
RHEI PHARMACEUTICALS ELECTS MRS. ZHENG HONG TO BOARD OF DIRECTORS
11/18/2008
TorreyPines Therapeutics Licenses Posiphen™, Bisnorcymcerine and Phenserine to QR Pharma
11/13/2008
Micromet to Present Interim Data from Two Studies for T Cell Engaging BiTE Antibody Blinatumomab at American Society of Hematolgy Annual Meeting
11/12/2008
TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
11/12/2008
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
11/10/2008
MediciNova Reports Third Quarter 2008 Results
11/10/2008
Researchers to Present Additional Data on Soliris® (eculizumab) for the Treatment of PNH at the ASH Annual Meeting
11/10/2008
TorreyPines Therapeutics Sells Alzheimer’s Disease Genetics Program to Eisai
11/10/2008
METHYLGENE REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS
11/6/2008
Living Cell Technologies Reports on 12-Month Clinical Effects of DiabeCell® at Annual General Meeting
11/4/2008
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
10/29/2008
Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States
10/27/2008
METHYLGENE REACQUIRES RIGHTS TO MGCD0103 FROM CELGENE AND IMPLEMENTS STRATEGIC PLAN TO FOCUS ON DEVELOPMENT OF PROPRIETARY CLINICAL PIPELINE
10/27/2008
METHYLGENE PRESENTS PRECLINICAL DATA FOR MGCD290, A HOS2 FUNGAL INHIBITOR, AT JOINT ICAAC/IDSA ANNUAL MEETING
10/23/2008
Living Cell Technologies Expands Breeding Capability with New Production Facility
10/23/2008
ALEXION REPORTS THIRD QUARTER 2008 RESULTS
10/22/2008
METHYLGENE PRESENTS PRECLINICAL BIOMARKER DATA FOR MGCD265 AT THE 20th EORTC-NCI-AACR-SYMPOSIUM
10/21/2008
Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
10/21/2008
Living Cell Technologies Receives Health Minister’s Approval to Start Leading Edge Live Cell Therapy Clinical Trial in New Zealand for Diabetics
10/20/2008
TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
10/17/2008
Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions
10/15/2008
METHYLGENE INITIATES PHASE I CLINICAL STUDY WITH MGCD290 FOR FUNGAL INFECTIONS
10/13/2008
CalciMedica Exercises Option to Acquire Additional Intellectual Property from TorreyPines Therapeutics
10/8/2008
CENOMED AND TORREYPINES THERAPEUTICS ENTER INTO LICENSING AGREEMENT
10/3/2008
Micromet Closes $40 Million Private Equity Placement
10/2/2008
METHYLGENE RECEIVES CLINICAL TRIAL APPROVAL FROM HEALTH CANADA FOR ITS PROPRIETARY PRODUCT CANDIDATE MGCD290
10/1/2008
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting with FDA for Tezampanel
9/30/2008
Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
9/25/2008
ALEXION’S SOLIRIS® RECEIVES 2008 PRIX GALIEN USA AWARD FOR BEST BIOTECHNOLOGY PRODUCT
9/25/2008
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
9/19/2008
METHYLGENE EXERCISES RIGHT TO CONVERT MGCD0103 COLLABORATION WITH CELGENE TO PRE-DETERMINED ROYALTY AND MILESTONE ARRANGEMENT
9/18/2008
Data from MediciNova’s Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis Presented at the World Congress for Treatment and Research in MS (WCTRIMS)
9/15/2008
Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
9/15/2008
Micromet Presents Data at ESMO 2008 on Anti- EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
9/9/2008
MediciNova Reports Positive Preliminary Results from Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
9/9/2008
SOLIRIS® REDUCED MEASURES OF THROMBOSIS AND INFLAMMATION, AND DECREASED INDICATORS OF PULMONARY HYPERTENSION, IN PATIENTS WITH PNH
9/2/2008
Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
8/26/2008
TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
8/25/2008
RHEI PHARMACEUTICALS APPOINTS DR. GEERT CAUWENBERGH AS CHIEF EXECUTIVE OFFICER
8/15/2008
METHYLGENE AND CELGENE PROVIDE UPDATE ON SUSPENSION OF NEW ENROLLMENT IN MGCD0103 CLINICAL TRIALS
8/11/2008
MediciNova Reports Second Quarter 2008 Results
8/8/2008
REDPOINT BIO REPORTS SECOND QUARTER AND SIX MONTH 2008 RESULTS
8/7/2008
Micromet, Inc. Reports Second Quarter 2008 Financial Results
8/7/2008
ALEXION SECURES U.S. PATENT FOR ALXN6000, A FIRST-IN-CLASS ANTI-CD200 MONOCLONAL ANTIBODY
8/4/2008
NEXMED CONFIRMS PUBLICATION OF NEW FEMPROX DATA IN THE JOURNAL OF SEXUAL MEDICINE
7/30/2008
METHYLGENE REPORTS SECOND QUARTER 2008 FINANCIAL RESULTS
7/29/2008
ALEXION REPORTS SECOND QUARTER 2008 RESULTS
7/22/2008
NEXMED RECEIVES FDA RESPONSE FOR ED PRODUCT
7/22/2008
METHYLGENE AND CELGENE ANNOUNCE PRECAUTIONARY SUSPENSION OF NEW ENROLLMENTS INTO MGCD0103 CLINICAL TRIALS
7/21/2008
REXAHN PHARMACEUTICALS RECEIVES U.S. PATENT FOR NEW CANCER COMPOUNDS
7/1/2008
NEXMED RECEIVES CASH INFUSION OF $5.75 MILLION
6/30/2008
Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
6/25/2008
METHYLGENE ANNOUNCES THE INITIATION OF A RANDOMIZED, THREE-ARM PHASE II TRIAL OF MGCD0103 IN COMBINATION WITH VIDAZA IN PATIENTS WITH HIGH-RISK MDS OR AML
6/24/2008
Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
6/23/2008
MediciNova Initiates Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
6/12/2008
METHYLGENE INITIATES SECOND PHASE I CLINICAL TRIAL WITH MGCD265, A MULTI-TARGETED (C-MET) KINASE INHIBITOR IN PATIENTS WITH SOLID TUMORS
6/12/2008
Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
6/5/2008
Micromet’s BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin’s Lymphoma
6/4/2008
TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
6/3/2008
METHYLGENE REPORTS CLINICAL DATA FROM A PHASE II STUDY EVALUATING MGCD0103 IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
6/3/2008
NEXMED CONFIRMS PUBLICATION ON ANTI-FUNGAL PRODUCT
6/2/2008
METHYLGENE REPORTS CLINICAL DATA FOR MGCD0103 AT THE 44TH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/16/2008
CLINICAL DATA FOR METHYLGENE’S MGCD0103 TO BE PRESENTED AT THE 2008 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
5/14/2008
NEXMED RECEIVES COMMITMENT FOR $3 MILLION LINE OF CREDIT
5/13/2008
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
5/12/2008
MediciNova Reports First Quarter 2008 Results
5/12/2008
MethylGene Reports First Quarter 2008 Financial Results
5/9/2008
REDPOINT BIO REPORTS FIRST QUARTER 2008 RESULTS
5/8/2008
NEXMED CONFIRMS DATA PRESENTATIONS ON ANTI-FUNGAL PRODUCT AT TWO PHARMA CONFERENCES
5/1/2008
TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
4/30/2008
ALEXION REPORTS FIRST QUARTER 2008 RESULTS
4/23/2008
Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
4/16/2008
METHYLGENE INITIATES PHASE I CLINICAL TRIAL FOR ITS MULTI-TARGETED(C-MET) KINASE INHIBITOR, MGCD265,IN SOLID TUMOR CANCERS
4/16/2008
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS MULTI-TARGETED (C-MET) KINASE INHIBITOR, MGCD265, AT AACR ANNUAL MEETING
4/15/2008
METHYLGENE PROVIDES UPDATE ON ITS MGCD0103 HDAC INHIBITOR COLLABORATION WITH CELEGENE
4/14/2008
Micromet Demonstrates that the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted into Highly Potent, T Cell-engaging BiTE Antibodies
4/14/2008
Micromet Presents Safety and Efficacy Data from Primate Studies with Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4/14/2008
METHYLGENE PRESENTS CLINICAL BIOMARKER DATA FOR MGCD0103 AND PRECLINICAL EFFICACY DATA IN COMBINATION WITH TAXANES AT AACR ANNUAL MEETING
4/14/2008
Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
4/7/2008
MediciNova Reports Clinical Results from Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
4/7/2008
Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
4/4/2008
METHYLGENE ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS AND CORRECTS PREVIOUSLY DISCLOSED INTERIM DATA FOR TRIAL 005
4/2/2008
MediciNova to Present Additional Clinical Data Demonstrating Potential Neuroprotection Benefits of MN-166 in Multiple Sclerosis at the 18th Meeting of the European Neurological Society
3/31/2008
MediciNova Initiates Phase II Clinical Trial of MN-221 in Status Asthmaticus Patients
3/31/2008
Gamma Secretase Modulators Show Promise in Alzheimer’s Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
3/27/2008
METHYLGENE ANNOUNCES WORLDWIDE RESEARCH COLLABORATION AND LICENSE AGREEMENT WITH OTSUKA PHARMACEUTICAL CO. LTD.
3/26/2008
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
3/25/2008
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
3/20/2008
Alexion Completes Enrollment in AEGIS Registration Study of Soliris ®(eculizumab) in Patients with PNH in Japan
3/18/2008
TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
3/17/2008
MediciNova Reports Fourth Quarter and Full Year 2007 Results
3/13/2008
Glycotex Completes Enrollment in Phase IIa Study of Lead Product Candidate GLYC-101 for Wound Healing
3/11/2008
REDPOINT BIO CORPORATION RECEIVES U.S. PATENT FOR METHOD OF IDENTIFYING MODULATORS OF KEY ION CHANNEL INVOLVED IN TASTE SIGNALING
3/10/2008
REDPOINT BIO REPORTS FOURTH QUARTER AND YEAR-END 2007 RESULTS
3/10/2008
REDPOINT BIO CORPORATION ANNOUNCES DISCOVERY OF MOLECULAR MECHANISM FOR THYMOL TASTE TRANSDUCTION
3/7/2008
METHYLGENE REPORTS FOURTH QUARTER AND FULL YEAR 2007 FINANCIAL RESULTS
3/5/2008
NEXMED CONFIRMS ACCEPTANCE OF NDS IN CANADA
2/14/2008
TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
2/14/2008
METHYLGENE AND PHARMION ANNOUNCE U.S. ORPHAN DRUG DESIGNATION GRANTED FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
2/14/2008
Alexion Reports Fourth Quarter and Full Year 2007 Results
2/14/2008
ALEXION ACQUIRES ALL RIGHTS TO OMRF PATENTS RELATED TO SOLIRIS®
2/11/2008
METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA
2/8/2008
MEDICINOVA REPORTS CASH, CASH EQUIVALENTS AND SHORT-TERM MARKETABLE SECURITIES AS OF DECEMBER 31, 2007 (UNAUDITED)
2/6/2008
METHYLGENE EXERCISES RIGHT TO OPT-OUT OF HDAC NEURODEGENERATIVE COLLABORATION WITH ENVIVO
2/5/2008
Multiple Dose Clinical Trial of TorreyPines Therapeutics’ Tezampanel Demonstrates Compound is Safe and Well-Tolerated
2/1/2008
MediciNova’s MN-166 Reduces Persistent Black Hole Formation
1/28/2008
METHYLGENE REPORTS MGCD0103 CLINICAL DATA AT THE 2008 GASTROINTESTINAL CANCERS SYMPOSIUM
1/14/2008
Access Licenses MuGard™ to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
1/9/2008
METHYLGENE AND PHARMION START PHASE II COMBINATION CLINICAL TRIAL WITH MGCD0103 AND VIDAZA® IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA OR NON-HODGKIN LYMPHOMA
1/7/2008
Alexion Commences Dosing in AEGIS Registration Study
12/20/2007
Redpoint Bio Names Joseph A. Mollica, Ph.D. Chairman of the Board
12/14/2007
Micromet Announces Changes in Management Team
12/14/2007
Redpoint Bio Signs Research & Technology Development Agreement with The Coca-Cola Company
12/11/2007
Alexion Pharmaceuticals, Inc PNH Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris® Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
12/10/2007
Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics’ Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
12/10/2007
METHYLGENE AND PHARMION PRESENT FAVORABLE CLINICAL DATA FROM COMBINATION MGCD0103/VIDAZA® STUDY IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOGENOUS LEUKEMIA AT THE 49th AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING
12/10/2007
Alexion Pharmaceuticals, Inc. LONG-TERM SOLIRIS® THERAPY IMPROVED OR STABILIZED KIDNEY FUNCTION IN PATIENTS WITH PNH
12/10/2007
Micromet and MedImmune Present New Clinical Data for MT103 at the American Society of Hematology Annual Meeting Suggesting Potent Single-Agent Activity in Patients with Relapsed Mantle Cell and Follicular Lymphoma
12/9/2007
METHYLGENE AND PHARMION REPORT FAVORABLE RESULTS FOR PHASE II MGCD0103 SINGLE-AGENT STUDIES IN RELAPSED OR REFRACTORY LYMPHOMAS AT THE 49TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) MEETING
12/7/2007
Alexion Pharmaceuticals to Present Data on Soliris® (Eculizumab)
12/5/2007
Curidium Announces Strategic Partnership with Takeda Research Investment, Inc. -Investment Focus on Major Depressive Disorder-
12/4/2007
SOLIRIS® DEMONSTRATES REDUCTIONS IN HEMOLYSIS AND IMPROVEMENTS IN FATIGUE, OVERALL QUALITY OF LIFE AND ANEMIA IN A BROAD POPULATION OF PNH PATIENTS
11/29/2007
METHYLGENE TO PRESENT CLINICAL DATA FOR MGCD0103 AT THE 49TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
11/15/2007
CATALYST PHARMACEUTICAL PARTNERS REPORST THIRD QUARTER 2007 FINANCIAL RESULTS
11/15/2007
NEXMED REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS
11/14/2007
PreMD Reports Third Quarter 2007 Results
11/14/2007
TorreyPines Therapeutics Reports Third Quarter 2007 Results
11/9/2007
MediciNova Reports Third Quarter 2007 Results
11/7/2007
METHYLGENE REPORTS THIRD QUARTER 2007 FINANCIAL RESULTS
11/5/2007
SKIN CHOLESTEROL LINKED TO CARDIOVASCULAR DISEASE RISK IN ASYMPTOMATIC INDIVIDUALS
10/25/2007
Alexion Reports Third Quarter 2007 Results
10/25/2007
MediciNova Announces Public Offering of Common Stock
10/24/2007
PreMD Announces Valuable Data on PREVU* LT Life Insurance Product
10/24/2007
METHYLGENE AND PHARMION REPORT PRELIMINARY MGCD0103 CLINICAL DATA AT THE 2007 AACR-NCI-EORTC INTERNATIONAL CONFERENCE
10/23/2007
Micromet Is Presenting Four Posters on BiTE® Antibodies at the International AACR-NCI-EORTC Conference
10/23/2007
Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
10/22/2007
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
10/22/2007
NEXMED FILES NDS IN CANADA
10/19/2007
MediciNova Reports Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia
10/18/2007
Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
10/17/2007
Tezampanel, TorreyPines Therapeutics’ Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10/10/2007
METHYLGENE AND PHARMION INITIATE PHASE I COMBINATION CLINICAL TRIAL WITH MGCD0103 AND TAXOTERE® IN PATIENTS WITH SOLID TUMORS
10/9/2007
MediciNova Reports Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus
10/5/2007
Redpoint Bio Chief Executive Officer, Dr. Ray Salemme, Featured in CEOcast Interview
10/3/2007
PreMD Inc. Provides Corporate Update
10/2/2007
METHYLGENE PROVIDES CORPORATE UPDATE AT ITS INVESTOR EVENT
10/1/2007
REDPOINT BIO NAMES SCOTT SIEGEL, PH.D. AS VICE PRESIDENT OF CORPORATE DEVELOPMENT
9/27/2007
Positive Clinical Data on MediciNova’s Product Candidate MN-029 Presented at the 14th European Cancer Conference (ECCO 14)
9/25/2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer’s Disease
9/24/2007
METHYLGENE AND PHARMION ANNOUNCE ORPHAN DRUG DESIGNATION GRANTED BY THE EUROPEAN MEDICINES AGENCY (EMEA) FOR MGCD0103 FOR THE TREATMENT OF HODGKIN’S LYMPHOMA
9/24/2007
NEXMED FILES NDA FOR PROPRIETARY ERECTILE DYSFUNCTION TREATMENT
9/19/2007
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS CLINICAL CANDIDATE MGCD290, AN ANTIFUNGAL HISTONE DEACETYLASE INHIBITOR
9/19/2007
ALEXANDRIA REAL ESTATE EQUITIES, INC. ANNOUNCES FOLLOW-ON PUBLIC OFFERING OF 2,000,000 SHARES OF COMMON STOCK
9/19/2007
ALEXANDRIA REAL ESTATE EQUITIES, INC. DECLARES QUARTERLY CASH DIVIDEND
9/12/2007
REDPOINT BIO APPOINTS NEW BOARD MEMBERS
9/12/2007
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
9/11/2007
MediciNova Announces Rule 10b5-1 Stock Purchase Plan
9/10/2007
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9/6/2007
PreMD Provides Update on 510(k) Application for PREVU* POC
9/5/2007
Columbia Laboratories and DesignRxclusive Increase Access to CRINONE 8% Progesterone Gel for Uninsured Patients
9/5/2007
AKELA PHARMA INC. ANNOUNCES POSITIVE RESULTS FOR THE EXTENSION PART OF ITS PHASE IIB FENTANYL TAIFUN® TRIAL
9/5/2007
Redpoint Bio Chief Executive Officer, Dr. Ray Salemme, To Be Interviewed Live On Market News First
9/4/2007
NATIONSHEALTH ACQUIRES DIABETES CARE & EDUCATION, INC.
8/27/2007
AKELA PHARMA INC. ENROLLS FIRST PATIENT IN ITS PHASE IIB CGRP TRIAL
8/27/2007
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
8/23/2007
New Breast Cancer Clinical Data Accepted for Presentation at San Antonio Breast Cancer Symposium
8/21/2007
METHYLGENE AND PHARMION ANNOUNCE U.S. ORPHAN DRUG DESIGNATION GRANTED FOR MGCD0103 FOR THE TREATMENT OF HODGKIN’S LYMPHOMA
8/20/2007
NationsHealth Warrants to Expire on August 24, 2007
8/20/2007
PNH Patients Treated with Soliris™ Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8/20/2007
METHYLGENE AND PHARMION ANNOUNCE COLLABORATION TO DEVELOP SIRTUIN INHIBITORS AS ANTI-CANCER AGENTS
8/17/2007
MediciNova Reports Phase Ib Clinical Study Results for MN-221, a Novel Treatment for Preterm Labor
8/15/2007
Redpoint Bio Announces Interview with WallSt.net
8/14/2007
REDPOINT BIO REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS
8/14/2007
NEXMED REPORTS SECOND QUARTER 2007 FINANCIAL RESULTS
8/14/2007
PreMD Reports Second Quarter 2007 Results
8/14/2007
AKELA PHARMA INC REPORTS RESULTS FOR SECOND QUARTER OF FISCAL 2007
8/14/2007
PASA Abstract to be presented at American Heart Association Conference
8/13/2007
TorreyPines Therapeutics Reports Second Quarter 2007 Results
8/10/2007
MediciNova Reports Second Quarter 2007 Results
8/9/2007
Data from MediciNova’s Phase II Trial of MN-166 Selected for Presentation at the 23rd Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) and the 12th Conference of Rehabilitation in Multiple Sclerosis (RIMS)
8/9/2007
MediciNova to Present Clinical Data on MN-029 at the 14th European Cancer Conference (ECCO 14)
8/9/2007
NATIONSHEALTH ANNOUNCES 2007 SECOND QUARTER AND YEAR TO DATE FINANCIAL RESULTS
8/8/2007
Micromet, Inc. Reports Second Quarter 2007 Financial Results
8/7/2007
METHYLGENE REPORTS SECOND QUARTER 2007 RESULTS
8/6/2007
TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8/1/2007
METHYLGENE REGAINS EXCLUSIVE RIGHTS TO BETA-LACTAMASE INHIBITOR PROGRAM FROM MERCK
7/30/2007
NATIONSHEALTH RECEIVES ACCREDITATION
7/25/2007
Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2007 Financial Results
7/25/2007
Alexion Reports Second Quarter 2007 Results
7/23/2007
AKELA PHARMA INC. COMPLETES PATIENT ENROLLMENT IN ITS FENTANYL TAIFUN® PHASE IIB TRIAL
7/20/2007
REDPOINT BIO CORPORATION ANNOUNCES EFFECTIVENESS OF REGISTRATION STATEMENT
7/19/2007
Micromet Promotes Carsten Reinhardt to Chief Medical Officer
7/16/2007
PreMD Signs Marketing and Distribution Agreement with AstraZeneca
7/16/2007
Alexandria Real Estate Equities, Inc. Celebrates 10th Anniversary on NYSE
7/12/2007
METHYLGENE INITIATES SINGLE-AGENT PHASE II CLINICAL TRIAL WITH ITS HDAC INHIBITOR, MGCD0103, IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
7/11/2007
TRACON Pharmaceuticals and Micromet Announce the Initiation of Phase 1 Clinical Trial with TRC093 (D93), a Humanized Antibody for Cancer Treatment
7/9/2007
NEXMED ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN TWO PIVOTAL PHASE 3 STUDIES FOR ANTI-FUNGAL PRODUCT
7/9/2007
NEXMED ANNOUNCES ITS INCLUSION IN THE RUSSELL MICROCAP® INDEX
6/29/2007
NEW TICKER SYMBOL FOR REDPOINT BIO CORPORATION
6/26/2007
MaRS Selects Alexandria Real Estate Equities to Expand the MaRS Centre in the Discovery District of Toronto
6/26/2007
MediciNova Announces New Strategic Initiative
6/26/2007
Publication Confirms that EpCAM, the Target for Two of Micromet’s Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
6/22/2007
ALEXION’S SOLIRIS™ GRANTED MARKETING APPROVAL IN EUROPE FOR TREATMENT OF ALL PATIENTS WITH PNH
6/20/2007
Micromet Announces Definitive Agreement for $25.0 Million Private Placement
6/20/2007
NEXMED APPOINTS VIVIAN LIU AS CHIEF EXECUTIVE OFFICER
6/20/2007
SCOTT HORVITZ OF REDPOINT BIO NAMED CFO OF THE YEAR BY NEW JERSEY TECHNOLOGY COUNCIL
6/19/2007
American Stock Exchange Accepts PreMD’s Continued Listing Plan
6/18/2007
ROBCOR PROPERTIES, INC. MERGES WITH AND INTO ITS WHOLLY-OWNED SUBSIDIARY REDPOINT BIO CORPORATION
6/18/2007
ALEXANDRIA REAL ESTATE EQUITIES, INC. DECLARES QUARTERLY CASH DIVIDEND
6/11/2007
STUDIES SHOW EFFICACY AND SAFETY OF ALEXION’S SOLIRIS™ IN BROAD POPULATION OF PNH PATIENTS
6/6/2007
PreMD Submits 510(k) to the FDA for Expanded Regulatory Claim for PREVU* POC
6/4/2007
SOLIRIS(TM) EFFECTIVE IN PNH PATIENTS WITH HISTORY OF APLASTIC ANEMIA AND MYELODYSPLASTIC SYNDROMES
6/4/2007
Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
6/4/2007
METHYLGENE REPORTS PHASE I DATA ON MGCD0103 IN ADVANCED LEUKEMIAS AND MYELODYSPLASTIC SYNDROME (TRIAL 004) AT ASCO
6/2/2007
METHYLGENE AND PHARMION REPORT PRELIMINARY DATA FOR MGCD0103 AT THE 43rd AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
5/31/2007
ADVANCED BIOHEALING CLOSES SECOND TRANCHE OF SERIES C FINANCING
5/29/2007
PreMD Inc. Receives Notice of Allowance for a United States Patent on PREVU* LT
5/24/2007
Micromet and Nycomed Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize anti-GM-CSF Antibodies for the Treatment of Inflammatory and Autoimmune Diseases
5/24/2007
METHYLGENE PRESENTS PRECLINICAL DATA FOR ITS CLINICAL CANDIDATE MGCD290 – AN ANTIFUNGAL HISTONE DEACETYLASE INHIBITOR
5/21/2007
REDPOINT BIO RELOCATES CORPORATE HEADQUARTERS AND RESEARCH FACILITY
5/17/2007
METHYLGENE SELECTS HISTONE DEACETYLASE ANTIFUNGAL CLINICAL CANDIDATE
5/14/2007
TorreyPines Therapeutics Reports First Quarter 2007 Results
5/12/2007
Curidium Announces Strategic Partnership with Takeda Research Investment, Inc. -Investment Focus on Major Depressive Disorder-
5/11/2007
PreMD Reports First Quarter 2007 Results
5/10/2007
NEXMED REPORTS FIRST QUARTER 2007 FINANCIAL RESULTS
5/10/2007
METHYLGENE REPORTS FIRST QUARTER 2007 RESULTS
5/9/2007
Micromet, Inc. reports first quarter 2007 financial results
5/7/2007
TorreyPines Therapeutics Transfers Intellectual Property and Compounds for Treating Autoimmune Diseases to CalciMedica
5/3/2007
ALEXANDRIA REAL ESTATE EQUITIES, INC. REPORTS FIRST QUARTER 2007 RESULTS
5/1/2007
Alexion Pharmaceuticals Reports First Quarter 2007 Results
4/27/2007
CHMP ADOPTS POSITIVE OPINION FOR ALEXION’S SOLIRIS™ IN EUROPE
4/26/2007
Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
4/25/2007
RIB-X PHARMACEUTICALS AND THE MEDICAL RESEARCH COUNCIL ANNOUNCE KEY COLLABORATION
4/19/2007
MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE® Molecule
4/18/2007
Micromet and MedImmune Present Data from Preclinical Study of New BiTE® Molecule Targeting CEA
4/17/2007
METHYLGENE PRESENTS CLINCAL BIOMARKER DATA FOR MGCD0103 AT AACR ANNUAL MEETING
4/16/2007
Alexandria Real Estate Equities, Inc. Announces Filing of Resale Shelf Registration Statement
4/12/2007
NATIONSHEALTH ANNOUNCES $7.0 MILLION TERM LOAN FACILITY
4/9/2007
REDPOINT BIO CORPORATION COMPLETES FINAL CLOSING OF $33 MILLION PRIVATE PLACEMENT
4/2/2007
Data on PreMD’s New PREVU* Tape POC Format to be Presented at American Association for Clinical Chemistry Meeting
3/29/2007
TorreyPines Therapeutics Reports 2006 Results
3/29/2007
PreMD Reports Fiscal 2006 Results and Provides Outlook for 2007
3/27/2007
Scientific Founder of TorreyPines Therapeutics Honored by Alzheimer’s Association
3/27/2007
Redpoint Bio Signs Multi-Year Research & Development Collaboration and Licensing Agreement with Givaudan
3/27/2007
NEXMED REPORTS 2006 YEAR END FINANCIAL RESULTS
3/21/2007
PreMD Announces Private Placement
3/16/2007
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
3/16/2007
FDA APPROVES ALEXION’S SOLIRIS™ FOR ALL PATIENTS WITH PNH
3/16/2007
Micromet, Inc. reports fourth quarter and full year 2006 financial results
3/15/2007
NATIONSHEALTH ANNOUNCES 2006 FOURTH QUARTER AND ANNUAL FINANCIAL RESULTS
3/13/2007
PreMD Provides Update on 510(k) Application for PREVU* LT
3/12/2007
REDPOINT BIO CORPORATION AND ROBCOR PROPERTIES, INC. COMPLETE REVERSE MERGER AND RAISE APPROXIMATELY $20 MILLION IN PRIVATE PLACEMENT TRANSACTION
3/12/2007
TorreyPines Therapeutics Initiates Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
3/8/2007
METHYLGENE REPORTS YEAR-END 2006 FINANCIAL RESULTS
3/7/2007
Publication Confirms that EpCAM, the Target for Two of Micromet’s Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
3/7/2007
Alexandria Real Estate Equities, Inc. Elects John L. Atkins, III to the Company’s Board of Directors
2/27/2007
Advanced BioHealing Raises $25.5 Million in Series C Financing
2/26/2007
TorreyPines Therapeutics Initiates Second Phase I Clinical Trial of NGX426, a Potential Novel Oral Treatment for Chronic Pain Conditions
2/22/2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Alzheimer’s Disease Collaboration Agreement
2/22/2007
Micromet, Inc. to Participate in Pacific Growth Equities One on One Sessions 2007: Oncology Conference
2/15/2007
Advanced BioHealing Launches Dermagraft®
2/12/2007
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and other Cancers
2/8/2007
Advanced BioHealing Enrolls First Patient in Celaderm™ Pilot Venous Leg Ulcer Clinical Trial
1/29/2007
Micromet Reports on First International Symposium on EpCAM Biology and Clinical Application
1/8/2007
PreMD Retains License Agreement for Cancer Patents
12/19/2006
Theratechnologies Reports Positive Phase 3 Results for TH9507 in HIV associated Lipodystrophy
12/15/2006
METHYLGENE TO INCREASE INVESTMENT IN HDAC AND KINASE (c-MET) SMALL MOLECULE PROGRAMS
12/11/2006
POSITIVE DATA REPORTED AT ASH ANNUAL MEETING FOR METHYLGENE’S MGCD0103, AN ORAL, ISOTYPE-SELECTIVE HDAC INHIBITOR
12/7/2006
METHYLGENE INITIATES PHASE II CLINICAL TRIAL WITH ITS PROPRIETARY HDAC INHIBITOR, MGCD0103, IN HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOGENOUS LEUKEMIA (AML)
12/7/2006
METHYLGENE SELECTS MULTI-TARGETED KINASE (C-MET) CLINICAL CANDIDATE FOR ONCOLOGY
12/6/2006
PreMD Announces Ontario Court Reserves Decision
12/5/2006
ARBIOS SYSTEMS CHIEF SCIENTIFIC OFFICER PRESENTS AT THE ACUTE LIVER FAILURE WORKSHOP, SPONSORED BY THE NIH
12/4/2006
METHYLGENE ANNOUNCES TWO POSTER PRESENTATIONS HIGHLIGHTING ITS LEAD HDAC INHIBITOR, MGCD0103, AT THE 48TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY
11/21/2006
PreMD Announces Order Issued in Maryland Court - Antisuit Motion Denied to Shamsuddin and Med-11 AG -
11/21/2006
ALEXION PHARMACEUTICALS ANNOUNCES CLOSING OF PUBLIC OFFERING OF STOCK
11/16/2006
METHYLGENE AND ENVIVO PHARMACEUTICALS FORM COLLABORATION WITH CHDI, INC., IN SUPPORT OF HDAC PROGRAM FOR HUNTINGTON’S DISEASE
11/15/2006
ARBIOS SYSTEMS ANNOUNCES ADDITION OF SENIOR PERSONNEL
11/15/2006
ALEXION PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
11/14/2006
ALEXION PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
11/14/2006
FDA Grants Priority Review for Soliris™ (eculizumab) BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria
11/9/2006
DATA FROM METHYLGENE’S ONCOLOGY PROGRAMS TO BE REPORTED AT THE 18th EORTC-NCI-AACR CANCER SYMPOSIUM IN PRAGUE
11/9/2006
Alexion Pharmaceuticals’ Soliris™ (Eculizumab) Data to be Presented at 2006 American Society of Hematology (ASH) Annual Meeting
11/9/2006
Micromet, Inc. reports third quarter 2006 financial results
11/9/2006
PreMD Reports Third Quarter Results
11/9/2006
COLUMBIA LABORATORIES REPORTS THIRD QUARTER 2006 FINANCIAL RESULTS
11/7/2006
Columbia Laboratories Advances Clinical Development of Lidocaine Candidate
11/6/2006
PreMD Submits 510(k) Application to FDA for PREVU* LT
11/6/2006
Antisuit Injunction Materials Served
11/2/2006
TorreyPines Therapeutics Completes Phase I Trial for NGX426, a Novel Oral Treatment for Pain
11/1/2006
METHYLGENE ANNOUNCES THIRD QUARTER 2006 RESULTS
11/1/2006
PreMD Announces Order Made by Judge in Ontario Court
10/31/2006
METHYLGENE TO PRESENT AT THE RODMAN & RENSHAW AND CIBC HEALTHCARE CONFERENCES
10/26/2006
METHYLGENE INITIATES PHASE I/II COMBINATION CLINICAL TRIAL WITH ITS PROPRIETARY HDAC INHIBITOR, MGCD0103, AND GEMZAR® IN PATIENTS WITH PANCREATIC CANCER
10/25/2006
Theratechnologies: last patient treated in pivotal TH9507 trial
10/25/2006
PreMD Commences Action in Ontario Court
10/25/2006
Micromet Presents New Anti-IL-2 Antibody with Unique Mode of Action
10/24/2006
ALANTOS PHARMACEUTICALS AND SERVIER FORM COLLABORATION
10/16/2006
TorreyPines Therapeutics Initiates Phase IIb Clinical Trial in Acute Migraine for Lead Compound Tezampanel
10/12/2006
Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
10/4/2006
TorreyPines Therapeutics Initiates Phase I Clinical Trial of NGX426, a Novel Oral Therapy for Migraine and Neuropathic Pain
10/4/2006
Syngenta’s corn rootworm biotech trait approved in the USA
10/3/2006
Syngenta obtains first regulatory approvals for new fungicide Revus™
10/2/2006
Final Data from Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
10/2/2006
A.P. PHARMA LICENSES APF530 TO RHEI PHARMACEUTICALS FOR DEVELOPMENT IN GREATER CHINA
9/29/2006
ARBIOS GRANTED FDA ALLOWANCE TO EXPAND SEPET™ CLINICAL TRIAL ELIGIBILITY
9/29/2006
METHYLGENE REPORTS PRECLINICAL RESULTS OF ITS ANTIFUNGAL COMPOUND MG3290 IN COMBINATION WITH AZOLES
9/27/2006
PreMD’s PREVU* LT Cleared For Sale in Canada
9/26/2006
License, Development and Supply Agreements to Terminate
9/25/2006
MorphoSys and U.S. Army Enter into Biodefense Cooperation
9/20/2006
PreMD Receives FDA Clearance for New Handheld PREVU* Reader
9/20/2006
Alexion Pharmaceuticals Submits Biologics License Application for Soliris™ (eculizumab)
9/20/2006
Soliris™ (eculizumab) Demonstrates Significant Improvement in PNH Study –Phase III TRIUMPH Study Published in
New England Journal of Medicine
–
9/18/2006
PreMD’s PREVU* LT Cleared For Sale in Europe
9/15/2006
METHYLGENE INITIATES PHASE II CLINICAL TRIAL WITH PROPRIETARY HDAC INHIBITOR, MGCD0103, IN B-CELL LYMPHOMA
8/22/2006
METHYLGENE’S HDAC INHIBITOR, MGCD0103, ENTERS PHASE II CLINICAL TRIAL IN PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN’S LYMPHOMA
8/21/2006
MedImmune Files Investigational New Drug Application for MT103
8/16/2006
ALANTOS PHARMACEUTICALS INITIATES PHASE 1 CLINICAL STUDIES WITH LEAD COMPOUND FOR TYPE II DIABETES
8/9/2006
NEXMED DEVELOPS ROOM TEMPERATURE FORMULATION OF ALPROX-TD FOR ERECTILE DYSFUNCTION
8/9/2006
Micromet, Inc. reports second quarter 2006 financial results
8/9/2006
NEXMED REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS
8/9/2006
PreMD Reports Second Quarter Results
8/9/2006
METHYLGENE ANNOUNCES SECOND QUARTER 2006 RESULTS
8/8/2006
Alexion Pharmaceuticals Reports Second Quarter 2006 Results
8/8/2006
PreMD’s New Handheld PREVU* Reader Cleared by Health Canada
8/3/2006
METHYLGENE TO PRESENT AT THE 2006 MEDICINAL CHEMISTRY GORDON CONFERENCE
8/1/2006
PreMD Receives CE Mark for New Handheld PREVU* Reader
7/27/2006
PreMD’s New LungAlert™ Test Format Presented at the 2006 AACC Annual Meeting
7/26/2006
PreMD Submits Special 510(k) Application to FDA for New Handheld PREVU* Reader
7/24/2006
TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer’s Disease
7/21/2006
MedImmune and Micromet Report on Novel Anti-cancer BiTE®
7/13/2006
Alexion Pharmaceuticals Purchases Biopharmaceutical Manufacturing Site in Rhode Island
7/12/2006
PreMD Reports Positive Interim Results from PREPARE Study
Copyright 2010 Rx Communications Group, LLC